Lonza buys InterHealth Nutraceuticals for $ 300 million

Lonza, the Switzerland-based provider of ingredients and services to the pharmaceutical, biotech and specialty ingredients companies, has agreed to acquire InterHealth Nutraceuticals Inc, the US-based manufacturer of value-added nutritional ingredients for use in dietary supplements, for $ 300 million. InterHealth is a portfolio company of Kainos Capital.

“With this acquisition Lonza is taking a further step along our strategic path as a high-value supplier to the healthcare continuum. Lonza will leverage the successful product portfolio of InterHealth on a global level and in turn will be able to benefit from InterHealth’s proven management and branding capabilities to promote Lonza’s existing product portfolio. We see significant positive synergies from this combination,” said Richard Ridinger, chief executive officer, Lonza.

InterHealth offers more than 15 branded ingredients, including its cornerstone ingredient, UC-II, which is revolutionising the joint-health segment; and it complements Lonza’s existing nutritional portfolio in the area of sports nutrition, weight management, immune health and pet health. The acquisition will also expand Lonza’s offerings into new areas such as cognitive and diabetic health.

Lonza is not only a custom manufacturer and developer, but it also offers services and products ranging from active pharmaceutical ingredients and stem-cell therapies to drinking water sanitisers, from the vitamin B3 compounds and organic personal care ingredients to agricultural products, and from industrial preservatives to microbial control solutions that combat dangerous viruses, bacteria and other pathogens. The company generated sales of CHF 3.8 billion in 2015 and is organised into two market-focused segments – specialty ingredients and pharma & biotech.